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ABSTRACT OF THESIS 
 
 
BISPHOSPHONATES AND BONE MICRODAMAGE 
 
 Osteoporosis is a significant healthcare issue due to the increasing elderly 
population.  Bisphosphonates are used to treat osteoporosis by reducing the rate of 
resorption, increasing bone mineral density (BMD) and thereby reducing fracture risk.  
Long-term bisphosphonate treatment, however, has been associated with low-energy 
fractures.   Bone microdamage may provide a partial explanation for one of the 
mechanisms responsible for these fractures since it has been shown to reduce bone 
toughness, fracture resistance, and bone strength.  The goal of this study was to quantify 
the changes in bone microdamage parameters with the duration of bisphosphonate 
treatment.   This study selected, stained, and histomorphometrically analyzed 40 iliac 
crest bone biopsies from controls and female patients with osteoporosis treated with 
bisphosphonates for varying durations (up to 12 years).  All subjects were matched for 
age and low turnover.  The results showed that microcrack density and microcrack 
surface density were significantly greater in patients who took bisphosphonates for at 
least 5 years compared to those who took bisphosphonates for less than 5 years or not at 
all.  These results reveal novel, clinically relevant information linking microdamage 
accumulation to long-term bisphosphonate treatment without influences from age or 
turnover. 
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CHAPTER I: GLOBAL INTRODUCTION 
 The older population in America is expanding rapidly.  In 2030 it is predicted the 
number of Americans over 65 years of age will grow to nearly 72.1 million, up from only 
39.6 million in 2009 (1).  The medical consequences of this increase will be a heightened 
awareness for preventing or treating aging-related disorders including cardiovascular 
disease, cancer, and musculoskeletal issues.  The most notable musculoskeletal issue is 
loss of bone mass and resulting propensity to incur bone fractures, i.e. osteoporosis. 
Osteoporosis  
The medical and economic issues accompanying osteoporosis have become 
increasingly concerning for at-risk adults as they age.  Nationally, osteoporosis affects an 
estimated 10 million Americans, and another 34 million are likely to develop 
osteoporosis as indicated by their low bone mass (2).  Osteoporosis is defined as a skeletal 
fragility condition caused by decreased bone mass and deterioration of bone 
microarchitecture, consequently increasing the risk of bone fracture (3).  Bone fractures 
are a strong concern for the aging population because of their association with long-term 
disability, psychosocial impairment, and overall reduced quality and quantity of life.  
Within one year of hip fracture, one third of patients are admitted to a nursing facility, 
and the fatality rate exceeds 20% for all hip fracture cases (2).  There are an estimated 1.5 
million osteoporotic fractures per year, and that number is likely to increase in the 
coming decades.  Costs associated with osteoporosis treatment, fractures, and post-
fracture care are a financial burden not only to patients but also to Medicare and the US 
as a whole, exceeding $20 billion nationally (2).  For example, one third of all fracture 
patients suffered from hip fractures, and their total individual cost for the year averaged 
at over $39,000 (2). 
Bone strength, or the ability of bone to withstand loading without failure, has 
been a key biomechanical parameter when discussing osteoporosis and understanding 
fracture risk.  Several properties influence overall bone strength from macro and 
microscopic perspectives such as BMD and bone microarchitecture, among others.  Bone 
mineral density (BMD) is quantified as the amount of mineral per area of bone and is 
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largely associated with bone strength since mineral stiffens the bone matrix.  It is 
common practice to measure a patient’s BMD to determine whether the patient is at risk 
for developing osteoporosis, has osteoporosis, and if the patient can benefit from anti-
resorptive treatments.  Patients are clinically defined as having osteoporosis if their BMD 
scores are “2.5 standard deviations below the mean for young, healthy adult women at 
any site.” (4)  However, although BMD is a strong indicator for fracture risk, BMD alone 
cannot predict which individuals will fracture (5, 6).  Alterations in bone mineralization 
will also affect bone strength.  Hypermineralized bone may be more brittle, occasionally 
caused by oversuppressed bone turnover.  Inversely, low mineralization, osteomalacia, 
reduces bone stiffness and strength  (7). 
Bone microarchitecture is another factor that affects bone strength and resulting 
fracture risk.  This refers to the connectivity of the trabecular “lattice” of cancellous bone.  
Bone resorption via post-menopausal osteoporosis will weaken the microarchitecture by 
reducing the trabecular thickness and reducing the number of connections between 
trabeculae.  Understandably, a thinner and less dense trabecular lattice will withstand less 
compressive force.  In fact, characteristics of bone microarchitecture have a stronger 
correlation with bone strength and are a better descriptor of fracture risk compared to 
BMD (8). 
 
Bisphosphonates 
Current osteoporosis treatments rely on suppressing bone turnover.  This serves 
the purpose of reducing bone resorption and subsequent weakening of the bone matrix 
responsible for the heightened fracture risk in osteoporotic patients.  Anticatabolic agents 
reduce excessive osteoclastic activity common in postmenopausal osteoporosis, and 
bisphosphonates have been the most prescribed anticatabolic agent over the past several 
decades.  Bisphosphonates alone do not actively build bone tissue to strengthen bone; 
they simply suppress bone resorption that counteracts new bone formation by osteoblasts 
(9). 
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The pyrophosphate chemical structure of bisphosphonate gives it a high affinity 
for bone mineral.  In fact, the skeleton will retain large amounts of bisphosphonate 
seemingly without saturation (10).  They will naturally bind to hydroxyapatite crystals 
exposed at bone remodeling sites which are especially abundant in high turnover bone 
(11).  The bisphosphonate molecule contains phosphate and hydroxyl groups responsible 
for its affinity for bone; however its two side chains make bisphosphonate especially 
appealing for clinical applications.  The side chains, as seen in Figure 1.1 (12), allow 
bisphosphonate to act as a drug carrier to treat skeletal diseases since it can bind strongly 
to bone or be easily excreted when unbound.  The presence of nitrogen in the R2 side 
chain increases the potency of bisphosphonate and alters its mechanism of action (10).  All 
modern bisphosphonates contain a nitrogen-based side chain including alendronate, 
risedronate, ibandronate, zoledronate, et al.   
Once bound to the exposed bone mineral, bisphosphonates are taken up by 
osteoclasts attempting to resorb bone tissue, where the drug negatively alters osteoclast 
activity or can cause apoptosis.  The more potent nitrogen-containing bisphosphonates 
affect osteoclasts by inhibiting FPP synthase, a key enzyme in the mevalonate pathway 
responsible for producing cholesterol and isoprenoid lipids such as geranylgeranyl 
diphosphate (GGPP) (13).  These isoprenoid lipids are considered building blocks for 
many metabolites and are essential for GTPases, signaling molecules responsible for 
cytoskeletal arrangement (13, 14).  The loss of these GTPase signaling molecules causes 
apoptosis in osteoclasts.  By these actions bisphosphonates can effectively inhibit 
osteoclastic bone resorption of hydroxyapatite.  A helpful side effect of bisphosphonate 
treatment is that it also possesses the ability to inhibit apoptosis of osteoblasts and 
osteocytes.  This secondary function may enhance the therapeutic efficacy of 
bisphosphonate treatment in addition to osteoclastic activity inhibition (15). 
 Bisphosphonates are typically prescribed to patients with BMD scores at 2.5 
standard deviations below normal (t-score: -2.5), the clinical definition of osteoporosis.  
However, it is also advised that bisphosphonates be prescribed to patients with BMD t-
scores between -1.0 and -2.5, defined as osteopenia, if they suffered from low-energy 
fractures or have a family history of poor bone health and fragility fractures.  They are 
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considered likely to develop further fractures and will benefit from bisphosphonate 
therapy.  For a patient with no history of fractures, fracture risk is based on BMD: 
osteoporotic patients should receive treatment, whereas osteopenic patients should not yet 
receive treatment.  Essentially, since BMD is not the only predictor of fracture risk, as a 
non-osteoporotic BMD score can still warrant bisphosphonate use if the patient 
experiences rare low-energy fractures, since reducing fracture risk is the primary 
objective of bisphosphonates  (16). 
 The patient’s rate of bone turnover before taking bisphosphonates can be a cause 
for concern.  Bone turnover suppression therapy will adequately suppress high turnover 
osteoporosis and reduce the elevated rate of bone resorption as intended.  However, it 
will also suppress low turnover osteoporosis often excessively to the point where the 
skeleton is unable to stimulate repair, and bone microdamage accumulates.  This has 
raised many questions about the long term effects of turnover suppression therapy and if 
there is a direct link between oversuppression of turnover and low-energy fractures 
indicating severe bone brittleness.  
Rare fractures 
Although it is well documented that bisphosphonate therapy widely reduces 
fracture risk and improves BMD, many publications report patients receiving atypical, 
spontaneous, non-traumatic fractures while on long term treatments of bisphosphonate (17-
21).  Shin et al. (21) reported a 63-year-old Korean woman who suffered non-traumatic 
diaphyseal fractures in both femurs while on bisphosphonates for 5 years despite lots of 
ambulatory activity and no prior fracture history.  Additionally, she experienced delayed 
healing after bone fixation surgery as a result of the oversuppression of both turnover and 
subsequent repair caused by prolonged bisphosphonate use.  Sellmeyer (20) described a 
58-year-old Caucasian woman who took bisphosphonates for 10 years after experiencing 
a foot stress fracture with test results indicating an osteopenic BMD.  After 10 years of 
therapy, she complained of thigh pain and suffered a complete subtrochanteric femur 
fracture while stepping down a stair.  She similarly experienced delayed healing due to 
bisphosphonate-induced turnover suppression.  Odvina et al. (18) examined 9 osteoporotic 
patients on alendronate therapy for 3-8 years who suffered non-traumatic fractures while 
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taking the medication.  All patients displayed severely suppressed bone turnover with 
evidence that alendronate was the culprit.  Fractures occurred in areas uncommon to 
osteoporosis, including the femoral shaft, ischium, and pubic bone.  Also, fracture 
healing was impaired or absent in 6 patients who continued taking alendronate after 
fracturing. 
 Not only are there many incidences of rare fractures in long-term bisphosphonate-
treated patients, but also certain characteristics of these fractures are common among 
them.  There exists an association between alendronate use and low-energy, transverse 
femur fractures through thickened diaphyseal cortices (22).  Neviaser et al. (22) reviewed 70 
patients with low-energy fractures, and 25 of them were being treated with alendronate.  
Seventy-six percent of the 25 exhibited simple, transverse fractures with a unicortical 
beak in a thickened cortex.  Only 2% of patients not being treated with alendronate 
shared the same fracture pattern.  Moreover, patients taking alendronate who exhibited 
the pattern have been taking the drug for significantly longer than those who did not 
exhibit the same pattern (6.9 versus 2.5 years of use). 
Lenart et al. (23) agree that this pattern is highly associated with bisphosphonate 
use.  Significantly more patients in Lenart’s study with subtrochanteric/femoral shaft 
fractures were taking bisphosphonates compared to the patients with 
intertrochanteric/femoral neck fractures.  It is concluded that these unusual fractures may 
result from unrepaired, propagating stress fractures and accumulated microdamage due to 
suppressed turnover from the duration of alendronate use. 
Safety and Duration of Use 
 Due to the many studies reporting atypical femur fractures in patients taking 
bisphosphonates for long periods, questions have arisen about the safety of 
bisphosphonates and optimal duration of use.  It is well understood that bisphosphonates 
improve BMD and reduce fracture risk in most patients; however, the existence of rare 
fracture incidences during long-term bisphosphonate use merits a re-examination of how 
long these drugs should be prescribed to ensure patient safety.  After all, the intent of 
taking bisphosphonate is to improve bone quality and reduce the risk of fractures. 
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 Unfortunately, stating an exact length of time for safe bisphosphonate use is 
difficult.  Numerous clinical factors such as patient age, BMD, fracture history, bone 
turnover rates, activity levels, and others all contribute to bisphosphonate’s potential to 
reduce fracture risk.  Plus, BMD and turnover are constantly changing during therapy.  
Therefore, it has been recently been advised to perform more thorough and individualized 
patient assessments of these variables to determine the proper duration of use by 
weighing the benefits versus potential risks (16, 24, 25). 
 Although no definite duration is considered completely safe from atypical 
fractures, several studies indicate 3-5 years is long enough for the average osteoporosis 
patient to take bisphosphonates to improve bone quality with little risk of atypical femur 
fractures, with some doctors recommending stoppage after 5 years if the patient’s BMD 
has significantly improved (24-26).  Watts and Diab (27) suggest an optimal-use window as 
large as 5-10 years for high-risk patients; however, that is certainly at the upper limit.  
Meijer et al (28) analyzed fracture rates in 14,750 women taking bisphosphonate for 
osteoporosis, and more than half stopped during the first year.  Compared to that group, 
those that took it for 3-4 years had significantly fewer fractures, but those that took it for 
5-6 years had slightly more fractures.  Similarly, Ott challenged a 2000 study about the 
skeletal benefits of 7 years of continuous alendronate by highlighting the fact that 
vertebral fractures were 3 times higher in years 6-7 compared to years 1-3 (29, 30).  
Additionally, other studies found that femur bone density increases then reaches a plateau 
after 3 years of bisphosphonate use (9, 31).  These findings support the notion that stopping 
bisphosphonate after 3-5 years will generally provide an adequate therapeutic response 
without increasing secondary fracture risk related to long-term bisphosphonate use. 
 
Microdamage 
Microdamage accumulation may explain the link between oversuppression of 
bone turnover and fracture occurrence.  Microdamage is defined as microscopic cracks in 
bone around 30-150 μm in length caused by cyclic fatigue stress.  The presence of minor 
microdamage is not inherently detrimental as it is caused by normal loading activities.  In 
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fact, a small amount of microdamage is considered beneficial since the formation and 
propagation of microscopic cracks are manifested releases of energy that could otherwise 
cause the bone to catastrophically fail (32).  Microdamage acts as a stimulus, through 
osteocyte apoptosis near the damage (33), to enable healthy bone to continually repair 
itself via turnover at a rate that sufficiently keeps up with microdamage formation (34, 35).  
On the other hand, when microdamage formation exceeds the rate at which bone can be 
repaired, bone quality can be compromised.  Bone with low or suppressed turnover, for 
example, cannot repair the microdamage quickly enough to keep up with microdamage 
formation.  Therefore, turnover suppression causes microdamage to accumulate and 
thereby alter the mechanical properties of bone (36). 
Greater microdamage accumulation significantly reduces bone toughness, fracture 
resistance, and bone strength (36, 37) resulting in strength and stiffness losses that are likely 
to increase fracture risk (38).  Also, microdamage density in both cortical and trabecular 
bone tends to increase with age, likely related to less remodeling and lower trabecular 
volume in older patients  (39, 40). 
  The parameters used to quantify microdamage are crack number (Cr.N), crack 
length (Cr.L), crack density (Cr.D), and crack surface density (Cr.S.D).  Cr.N is the 
number of cracks found in each specimen, although this parameter is more useful when 
the area of bone in each specimen is taken into account.  Cr.L is the length of the crack 
along its path measured in μm.  Cr.D is defined as the number of cracks per mm2 of bone 
area.  Lastly, Cr.S.D is defined as the total length of all cracks in a specimen per mm2 of 
bone area.  Cr.D and Cr.S.D are the most commonly used parameters to quantify 
microdamage accumulation, as they account for the varying bone areas, especially when 
studying trabecular bone.   The length of microcracks has been suggested to be an 
important factor in fatigue resistance since bone that that allows cracks to form but not 
grow should be resistant to fracture (41).  On the contrary, other studies showing 
significant changes in microdamage accumulation report no change in crack length (42, 43). 
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Microdamage Detection 
 The most common procedure for identifying bone microdamage is Burr and 
Hooser’s en bloc basic fuchsin staining method (44) which evolved from previous 
microdamage detection methods (35, 45).  This procedure uses a series of graded alcohols in 
solution with basic fuchsin to stain in vivo microcracks before sectioning.  The graded 
alcohols serve to slowly dehydrate the bone tissue to avoid causing ex vivo cracks 
associated with quick dehydration.  After sectioning, thin slices of the sample are 
examined under light microscopy to identify microcracks and measure the previously 
mentioned crack parameters to quantify the amount of microdamage. 
 Over the past two decades, a variety of approaches have been developed to 
identify microdamage as an alternative to using only light microscopy.  Although the 
light microscopy method has proven validity, its microcrack detection involves varying 
the depth of focus, light intensity, and magnification to correctly distinguish stained 
cracks from artifactual ones (46).  For example, Lee et al. (46) showed that fluorescence 
microscopy could be used to aid in detecting microcracks.  Samples were stained via the 
same en bloc basic fuchsin staining method; however, slices were examined using both 
light microscopy and epifluorescence.  Results between the two had no statistical 
differences, proving fluorescence microscopy can be a reliable alternative to light 
microscopy.  Another technique is laser scanning confocal microscopy (LSCM).  This 
process focuses laser light onto the bone surface and excites fluorochromes within the 
stained microcracks to produce a three-dimensional, high resolution representation of 
each microcrack (47). 
 Beyond the application of microcrack detection for the purpose of quantifying 
microdamage accumulation, staining techniques have also been used to track the 
propagation of microcracks.  Multiple stains, in this case chelating fluorochromes, bond 
to the exposed hydroxyapatite present in microcracks and are visible using fluorescent 
microscopy (48).  To track microcrack growth, bone samples are mechanically stressed in 
cyclic compression to initiate microdamage in several sequential stages.  In between 
stages, the samples are stained with a different chelating fluorochrome in a specific order 
based on bonding affinity to properly label cracks (49).  The result is an assortment of 
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multi-colored microcracks that reveal the shape, time, and direction of crack propagation 
based on the progression of stain colors. 
 
Thesis Research Goal 
 Reports of fragility fractures in patients on bisphosphonate treatments raise 
concerns about this class of drug’s long-term safety.  The link between microdamage 
accumulation and bisphosphonate use has mainly been explored in animal models using 
accelerated treatment dosages, and research using human bone is extremely limited.  
Therefore, the purpose of this study is to address these prior limitations by studying 
human bone from patients which used bisphosphonates for actual clinical treatment of 
varying (0-12 years) durations.  
The specific aim of this research is to quantify microdamage in iliac crest bone 
biopsies of osteoporotic patients to determine if there is an association between 
microdamage accumulation and long-term bisphosphonate use.  The hypothesis is that 
long-term bisphosphonate use is associated with greater microdamage accumulation 
compared to short-term and no bisphosphonate use. 
 
 
Figure 1.1: Basic chemical structure of bisphosphonate. (12) 
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CHAPTER II: MANUSCRIPT 
 
Microdamage in Bisphosphonate Treated Human Bone. 
 
William A Caruthers, MS-candidate1 
Hartmut H Malluche, MD2 
Marie-Claude Monier-Faugere, MD2 
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1Center for Biomedical Engineering, University of Kentucky, 600 Rose St. Lexington, 
KY 40506-0070 
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Summary 
Bisphosphonates (BPs) have served as an effective short-term treatment for osteoporosis; 
however, prolonged BP use may adversely affect bone quality.  The goal of this study 
was to analyze iliac crest bone biopsies from postmenopausal osteoporotic women to test 
the hypothesis that there is no difference in microdamage accumulation among: 1) 
patients treated with long-term BP use (≥5 yr, n=15), 2) patients treated with short-term 
BP use (<5 yr, n=14), or 3) untreated, age- and turnover-matched osteoporosis patients 
(n=11).  Bone samples from each of these three subject populations were stained en bloc 
with basic fuchsin then sectioned for microdamage analysis by using light and fluorescent 
microscopy.  Microdamage was quantified by measuring microcrack length (Cr.L), 
density (Cr.D), and surface density (Cr.S.D) and was compared between groups.  Cr.D 
and Cr.S.D were 76% and 87% greater (Cr.D, p=0.01; Cr.S.D, p=0.02) in the long-term 
BP group compared to the short-term BP group and were 27% and 29% greater (Cr.D, 
p=0.02; Cr.S.D, p=0.04) compared to the control group.  No differences in crack length 
were detected among these groups. 
 
Keywords: bone microcracks, alendronate treatment, anti-resorptive treatment, fragility 
fractures 
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Introduction 
 Bisphosphonates (BPs) have been used for nearly 2 decades as a proven anti-
resorptive therapy to treat osteoporosis by reducing osteoclastic activity, thus increasing 
BMD and reducing fracture risk in women with postmenopausal osteoporosis.  This 
inhibition of bone resorption by osteoclasts is maintained throughout the treatment 
duration (50).  BP treatment for up to 3-5 years has been shown to effectively reduce 
fracture risk (31, 50).  Long-term (> 5 years (9)) BP use has been the subject of growing 
concern in recent years as it may induce oversuppression of bone turnover and impair the 
biomechanical properties of bone.  Reports have surfaced regarding patients experiencing 
non-traumatic fractures while on BP therapy for 5-12 years (17-21).  In fact, the American 
Society for Bone and Mineral Research found that 94% of patients with atypical femur 
fractures had been taking BP treatments, most for over 5 years (51). 
Changes in bone microdamage may be partially responsible for the link between 
long-term BP use and atypical femur fractures.  BPs not only reduce bone turnover but 
they also suppress targeted remodeling essential for repairing microdamage (52).  
Accumulated microdamage as a result of prolonged BP treatment has been shown to 
reduce canine bone toughness, essential for fracture prevention (36).   Data exist showing a 
difference in microdamage in BP-treated patients, but there is no distinction between 
short- and long-term BP use, and the rate of bone turnover could not be determined in the 
control subjects (53).  The present study seeks to improve upon prior studies by comparing 
long-term BP patients to age-matched and turnover-matched groups of short-term BP-
treated patients and untreated control patients. 
The specific aim of this research was to determine if the duration of BP treatment 
is associated with changes in bone microdamage in patients with postmenopausal 
osteoporosis. 
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Materials and Methods 
Study Design 
This laboratory study was designed to compare the effects of long-term BP 
treatment versus short-term or no BP treatment on microdamage accumulation in human 
bone from postmenopausal osteoporosis patients by using histological microdamage 
analysis.  Subject groups were matched for age and turnover to eliminate their effects on 
bone microdamage and isolate only the effects from the duration of BP treatment.  BP 
treatment duration (independent variable) was analyzed as a function of microcrack 
length, density, and surface density (dependent variables). 
Subject Inclusion and Exclusion Criteria 
Anterior iliac crest bone biopsies were obtained from low-turnover, 
postmenopausal, osteoporotic, Caucasian female patients between 41–74 years of age 
with no history of smoking or diabetes.  Most treated patients took Fosamax 
(alendronate), whereas others took risedronate, ibandronate, or zoledronate.  Biopsies 
were separated into three groups: 11 patients with no previous BP therapy, 14 patients 
with less than 5 years of BP therapy (2.66 ± 1.1 yr duration), and 15 patients with 5 years 
or more BP therapy (8.57 ± 2.6 yr duration), with no differences in age or turnover 
between groups. 
Patients were excluded if they had: a diagnosis of osteogenesis imperfecta or 
other genetic bone disease, osteomalacia, hyperparathyroid bone disease, chronic kidney 
disease, endocrine abnormalities, diabetes, Paget’s disease of bone, malignancies, history 
of drug or alcohol abuse, teriparatide, SERMs, sex steroids, or any other medications 
known to alter bone metabolism.  The protocol of this IRB approved study adhered to the 
Declaration of Helsinki. 
Specimen Preparation 
Bone specimens were previously embedded in MMA and were immersed in 2-
methoxyethyl acetate for 3-4 weeks while agitated until the plastic was completely 
removed.  Staining solutions were made from solutions of 1% basic fuchsin (JT Baker, 
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B660-03, Phillipsburg, NJ) in 80%, 90%, and 100% ETOH and stirred overnight.  Each 
biopsy was stained en bloc using a previously established protocol (44) in the following 
solutions under vacuum: 
1. 48h: 70% ETOH 
2. 2h: 1% basic fuchsin in 80% ETOH 
3. Change solution 
4. 2h: 1% basic fuchsin in 80% ETOH 
5. Repeat steps 2-4 for 1% basic fuchsin in 90% ETOH 
6. Repeat steps 2-4 for 1% basic fuchsin in 100% ETOH 
7. Rinse in 100% ETOH to remove excess stain 
 
Stained bone specimens were re-embedded in MMA and then sectioned by using a 
diamond-bladed band saw (Model 300, EXAKT, Oklahoma City, OK) into 4-5 slices, 
each 150-300μm thick.   
Microdamage Assessment 
Light and fluorescence microscopy connected to histomorphometry software 
(OsteoMeasureXP V1.01, OsteoMetrics, Decatur, GA) was used to measure established 
crack parameters in trabecular bone: crack length (Cr.L, µm), crack density (Cr.D, 
cracks/mm2), and crack surface density (Cr.S.D, total Cr.L/mm2).  Cr.D shows how many 
cracks exist within a given bone area, and Cr.S.D quantifies the total lengths of all cracks 
in that area.  The thinnest slice for each specimen was viewed under 200x magnification 
(Axioplan 2 Imaging, Carl Zeiss, Thornwood, NY) to examine an optical field of view of 
485 x 365μm.  Starting at the center of each specimen, 50 optical fields containing bone 
were viewed for microdamage analysis totaling 8.85mm2 of tissue.  Crack number (Cr.N, 
#) standard deviation stabilized after 50 optical fields, indicating this amount of bone 
analysis provided an accurate representation of the specimen’s microdamage.  Stained 
microcracks were identified by their sharp borders, stain penetration through crack walls, 
visibility while altering depth of field, and intermediate size being larger than canaliculi 
but smaller than vascular channels (45). Microcracks longer than 30μm were recorded 
because this was the lower limit for reliable microcrack detection (49).  All measurements 
were performed by a single observer blinded to specimen group affiliation. 
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Bone Histology: Activation Frequency 
Bone samples were processed without mineral removal and were embedded in 
methylmethacrylate following tetracycline double-labeling.  Serial sections of 4- to 7μm 
thickness were cut and stained with modified Masson-Goldner trichrome.  Unstained 
sections were prepared for fluorescent and polarized light microscopy (54).  
Histomorphometry was done at standardized sites in cancellous bone to obtain activation 
frequency (Ac.f, cycles/yr). 
Statistical Analysis 
Data were tested for normality by using the Shapiro-Wilk test.  Normally distributed data 
were analyzed by using the one-way ANOVA test.  Non-normally distributed data were 
analyzed by using Kruskal-Wallis and Mann-Whitney U tests.  The Pearson’s R test was 
used to test correlations of normally distributed microcrack parameters with BP duration, 
age, and Ac.f.  The Spearman rank test was used to test correlations of non-normally 
distributed data.  All computations were done by using SPSS version 20 (IBM SPSS Inc, 
Chicago, IL).  
 
Results 
 Microcrack density and surface density in bone from patients receiving long-term 
BP treatment were significantly greater compared to both short-term BP treatment and 
control groups (Table 1).  Microdamage parameters were not normally distributed, and 
thus the median Cr.D in long-term BP treated patients was 76% greater (p = 0.009) 
compared to short-term BP treated patients and 27% greater (p = 0.016) compared to 
controls.  Similarly, the median Cr.S.D in long-term BP treated patients was 87% greater 
(p = 0.016) than short-term BP treated patients and 29% greater (p = 0.040) than controls.  
When comparing the control group to short-term BP patients, there were no differences in 
microdamage parameters.  With 80% power at a 95% confidence level, in order to see 
differences in microdamage parameters between the control and short-term BP groups, 
the number of subjects in each group must equal 39,470 for Cr.L, 320 for Cr.D, and 1,723 
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for Cr.S.D.  Intraobserver variation accounted for differences of less than 2% in 
microdamage parameter measurements. 
 Crack density correlated with BP treatment duration (rho = 0.36, p = 0.023, Fig. 
2.1), whereas Cr.S.D and mean Cr.L showed no correlation to BP duration (Fig. 2.2, 2.3).  
Cr.D was unrelated to the age of the subjects (rho = 0.27, p = 0.096, Fig. 2.4) or the rate 
of bone turnover (rho = 0.04, p = 0.843, Fig. 2.5).  The same applies for the Cr.S.D. and 
mean Cr.L parameters. 
 
Discussion 
 The two chief findings of this study are that postmenopausal osteoporotic women 
who took BP for at least 5 years had greater density of microcracks compared to those 
who took BP for less than 5 years or not at all and that the mean length of these cracks 
could not be associated with changes in length as a function of BP treatment duration.  
These results, obtained from an age and turnover-matched population, reveal novel, 
clinically relevant information about bone microdamage and BP treatment durations.  
This suggests that prolonged BP use is associated with mechanisms responsible for crack 
initiation, but perhaps not propagation.  Although microdamage has been shown to 
weaken bone tissue (36), the inability to observe a change in mean crack length may 
indicate that these microcracks, regardless of density, are not propagating and coalescing.  
These findings add new information regarding bone microdamage and BP treatment 
duration. 
Few microdamage studies of human bone treated with BPs are reported in the 
literature.  A prior study compared BP patients to an unmatched control group composed 
of cadaver specimens with unknown clinical histories and revealed that more than half of 
the treated and control specimens contained no microdamage (53, 55).  Although it claims 
BP has no effect on microcrack frequency, the ability of that study to verify the 
relationship between BP use and microdamage remains unclear.  Another study showed 
increased microdamage accumulation in women treated with alendronate for an average 
of 5 years (43).  Both the increase in crack surface density and unchanged crack length 
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resulting from BP use agree with the findings of the present study.  An additional study 
also supports the present finding that BP treatment had no effect on crack length as 
previously stated (42).  The present study is the only human study to compare 
microdamage from prolonged BP therapy to short-term BP therapy as well as no-BP 
controls.  The addition of the short-term BP group may help further identify the 
deleterious effects of long-term BP on bone health and help better distinguish a safer 
duration of BP use for treating postmenopausal osteoporosis. 
 The fact that only the long-term treatment group had greater microcrack density 
and surface density is a significant finding because it conveys that the increase in 
microdamage associated with BP treatment is not present in most patients who took BPs 
for under 5 years.  This could be attributed to the increased BMD that is associated with 
short-term treatments before extensive microdamage initiation occurs, effectively 
increasing crack density and surface density. 
 Since there are no differences in turnover or age between groups, the increased 
microdamage density observed in long-term BP treated patients may be attributed to an 
intrinsic effect of BP promoting microcrack initiation instead of only the suppression of 
turnover.  One possibility is the accumulation of AGEs (advanced glycation end-
products) that result from non-enzymatic collagen cross-linking induced by BP treatment 
(55, 56).  AGEs have been shown to increase the brittleness of bone tissue (57) and may 
contribute to the reported reduced bone toughness associated with BP treatment (42, 58).  
Increased microcrack density may result from this AGE-accumulation and subsequent 
induced bone embrittlement since it increases the potential for microcracks to initiate (55). 
This study is limited to BP treatment duration related changes in cancellous bone 
microdamage; microdamage measurements were not made in cortical bone due to the 
inability of the stain to penetrate to the same degree.  Also, not all biopsy specimens 
contained sufficient quantities of cortical bone.  Furthermore, this study did not focus on 
a particular type of BP since the specific BP drug used varied among treated patients.  It 
is worthy to note, however, that 79% of the treated study subjects used Fosamax 
(alendronate).  More work is needed to determine if the results reported are equally 
applicable for each particular BP on the market. 
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In conclusion, compared to untreated controls or those treated for short durations 
(< 5 years) with BP, long-term (≥5 years) BP treatment was associated with increased 
microcrack density in age- and turnover-matched groups of postmenopausal osteoporotic 
women.  No evidence was obtained linking significant increases in microcrack length to 
bisphosphonate treatment duration. 
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Table 2.1: Subject Data and Microdamage Parameters 
  Control (No BP) 
(n = 11) 
Short‐term BP (<5 yr) 
(n = 14) 
Long‐term BP (≥5 yr) 
(n = 15) 
Age  53 (49 – 70) 60 (41 – 74) 62 (54 – 73)
Ac.f (cycles/yr)  0.09 (0.02 – 0.26)  0.11 (0.04 – 0.48)
a  0.14 (0.03 – 0.37)
b 
BP treatment duration (yr)  0 (±0) 2.63 (±1.2)* 8.57 (±2.6)*†
Microdamage Parameters   
    Mean Cr.L (μm)  67.9 (±11.0) 68.2 (±12.9) 69.2 (±9.9)
    Cr.D (#/ mm2)  3.74 (1.78 – 5.38) 2.22 (1.23 – 7.38) 4.94 (2.81 – 7.06)*†
    Cr. S.D (total Cr.L μm/ mm2)  263 (101 – 372) 140 (76.5 – 607) 355 (184 – 528)*†
Parametric data expressed as mean(±SD).
Non‐parametric data expressed as median(min‐max). 
*p < 0.05, compared to control group. 
†p < 0.05, compared to short‐term group. 
a
 n = 10; 
b
 n = 11 
 
 
 
Figures 2.1 – 2.3: Correlations between microdamage parameters and BP duration show a 
significant relationship between Cr.D and BP duration but not between Cr.S.D or Cr.L 
and BP duration. 
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Figures 2.4 – 2.5: Neither age nor Ac.F show a strong relationship with Cr.D. 
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CHAPTER III: CONCLUDING REMARKS 
Importance 
The present study is important due to its novel assessment of bone microdamage in 
human bone from women treated with bisphosphonates for short and long durations (up 
to 12 years), and the age- and turnover-matching between groups, including untreated 
controls.  Age and turnover matching was significant because it allowed their effects on 
microdamage accumulation to be eliminated and the effects of bisphosphonate treatment 
duration to be isolated. Significant changes in microdamage accumulation following 5 or 
more years of treatment imply a distinct change in bone quality associated with 
prolonged bisphosphonate exposure that allows for easier microcrack initiation. 
Although the present study shows long-term bisphosphonate therapy is associated 
with greater microdamage accumulation in postmenopausal women, there is no evidence 
that such microdamage is associated with the reported atypical fractures.  However, 
studies show microdamage can reduce the mechanical properties in bone, although the 
exact quantity of microdamage that induces clinically-relevant amounts of bone fragility 
is still unknown and requires further work to establish. 
 
Limitations 
 This research focused only on microdamage in trabecular bone instead of cortical 
bone, which could be a possible limitation since atypical femur fractures occur within 
primarily cortical bone tissue.  On the other hand, bisphosphonate-induced microdamage 
accumulation in trabecular bone may not be dissimilar to microdamage accumulation in 
cortical bone.  For example, previous studies have shown cortical microdamage 
accumulated in dogs when treated with bisphosphonate (36, 61).  Trabecular microdamage 
has actually been shown to initiate before cortical microdamage.  In a study that loaded 
rat vertebrae in axial fatigue tests, trabecular microdamage initiated and propagated 
before microdamage in the cortical shell  (62).  If atypical fractures are indeed influenced 
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by cortical microdamage, perhaps they are preceded by trabecular microdamage 
accumulation that contributes to diminishing the structural integrity of bone.    
 
Future Directions of Research 
 The future of microdamage research might focus on the mechanisms behind 
microcrack initiation, or lack of propagation as influenced by long-term bisphosphonate 
use, for the purpose of revealing details about its possible direct or indirect causality.  In 
order to investigate the effect of bisphosphonate on microcrack initiation, bone specimens 
from animals treated with alendronate were fatigue loaded and compared to untreated 
specimens.  Alendronate-treated bone contained significantly more microdamage than the 
untreated bone after identical fatigue loading (63).  This agrees with the current study’s 
finding that bisphosphonate treatment is associated with the presence of increased 
microdamage.  Similarly, it has been shown that one year of alendronate in dogs reduced 
trabecular bone’s ability to resist loading-induced severe and linear microcrack formation 
(64).  Although these studies show bisphosphonate therapy alters bone’s ability to resist 
microdamage formation, the mechanism behind the interaction of bisphosphonate and 
bone that permits microcracks to form is not yet understood. 
It has already been shown that the propagation of microcracks can be tracked 
using multiple stains between mechanical fatigue loading sessions (48), but no studies 
have monitored crack propagation in bisphosphonate-treated bone with this method.  
Work has been done using finite element methods to assess crack growth in cortical bone 
microstructures and learn what factors affect it, such as cement lines, osteon strength, and 
fracture toughness (65).  Future finite element analyses could help expand the working 
knowledge of crack mechanics in bone, especially in trabecular bone or specimens 
treated with bisphosphonate.  
 A more comprehensive approach to bisphosphonate-induced microdamage 
research would be the inclusion of material and mechanical property analyses to obtain a 
better understanding of the mechanisms behind the association between bisphosphonates 
and microdamage accumulation.  In addition to histology and microdamage detection, the 
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same bone specimens from long-term bisphosphonate-treated, short-term, and untreated 
patients should be analyzed with nanoindentation and Fourier transform infrared 
spectroscopy (FTIR) to gain insight on their individual mechanical and material 
properties.  Uncovering links between prolonged bisphosphonate use, microdamage, 
collagen cross-linking, mineralization, fracture toughness, and modulus, for example, in 
clinically relevant human bone would offer novel information. 
 
Conclusion 
  Long-term bisphosphonate use is associated with significantly more microdamage 
accumulation, i.e. greater crack density and greater crack surface density, compared to 
short-term bisphosphonate use and untreated patients.  No evidence was obtained linking 
significant increases in microcrack length to bisphosphonate treatment duration. 
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